Sunshine Biopharma prices $6 million common unit public offering
SBFM•Sunshine Biopharma priced a public offering expected to raise about $6 million in gross proceeds. It includes 10,909,083 common or pre-funded units priced at $0.55 each.
1. Offering details
Each unit includes two Series D warrants exercisable at $0.66 and expiring five years after issuance. The closing is expected around Oct. 9, 2026, subject to customary conditions.
2. Use of proceeds
Net proceeds are earmarked for general corporate purposes, including working capital.
